Lundbeck, Longboard
Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Lundbeck acquires Longboard Pharmaceuticals in $2.6 billion deal
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on LBPH stock here.
Longboard Pharmaceuticals Stock Soars 51%. It’s Being Bought for $2.6 Billion.
Pharmaceutical company Lundbeck will acquire Nasdaq-listed Longboard Pharmaceuticals in a $2.6 billion deal, the two companies said Monday. Denmark-listed H. Lundbeck will make a tender offer for all shares outstanding of Longboard common stock,
Lundbeck picks up Longboard Pharmaceuticals for $2.6B
Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker stated.
Lundbeck to buy neurology-focused Longboard Pharmaceuticals in $2.6 billion deal
The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals in a deal worth $2.6 billion
Denmark's Lundbeck Bets on Epilepsy Drug With $2.6 Billion Longboard Deal
(Reuters) -H Lundbeck A/S has agreed to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion, marking the biggest deal ever by the Danish drugmaker as it seeks to bolster its portfolio with a potential blockbuster epilepsy drug.
Longboard Pharmaceuticals Inc (LBPH) Stock: More Resilient Than It Appears
On Monday, Longboard Pharmaceuticals Inc (LBPH) stock saw a modest uptick, ending the day at $58.99 which represents a slight increase of $20.09 or 51.65% from the prior close of $38.9. The stock opened at $58.
Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?
H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. The acquisition strengthens Lundbeck's pipeline with bexicaserin, a potential treatment for Dravet syndrome and other neurological conditions.
Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal
Danish pharmaceutical company H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals Inc in a deal with an equity value of $2.6 billion.
Denmark's H. Lundbeck To Buy Longboard Pharmaceuticals For $60/share Cash
Danish pharmaceutical company H. Lundbeck A/S (HLUKY.PK, HLUKF.PK) and Longboard Pharmaceuticals, Inc. (LBPH), announced Monday an
FierceBiotech4d
Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...
pharmaphorum4d
Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an ...
El gigante farmacéutico danés compra el fármaco contra la epilepsia de una empresa de San Diego
Lundbeck, una farmacéutica global con sede en Dinamarca, ha acordado comprar Longboard Pharmaceuticals, con sede en La Jolla, ...
Strong Valuation and Strategic Acquisition Drive Buy Rating for Longboard Pharmaceuticals
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Longboard Pharmaceuticals (LBPH – Research ...